Deoxyribonucleic acid (DNA) and DNA synthesis machinery (DNA)

Deoxyribonucleic acid (DNA) and the associated DNA synthesis machinery represent the critical cellular targets for the active metabolites of gemcitabine, a pyrimidine antimetabolite used extensively in cancer therapy (StatPearls, 2023). Gemcitabine is a prodrug that requires intracellular conversion into gemcitabine diphosphate (dFdCDP) and gemcitabine triphosphate (dFdCTP) to exert its cytotoxic effects (PubChem, CID 60750). dFdCTP is incorporated into the DNA strand by DNA polymerases during the S-phase of the cell cycle, where it induces "masked chain termination" (Plunkett et al., 1995). This process allows for the addition of only one additional nucleotide after the analog, which prevents the 3' to 5' exonuclease activity of DNA polymerase from excising the drug, ultimately leading to DNA strand breaks and programmed cell death (Miniotti et al., 2021). Concurrently, dFdCDP inhibits ribonucleotide reductase, the enzyme responsible for producing deoxyribonucleotides, thereby lowering the concentration of competing natural nucleotides and potentiating the drug's efficacy (Heinemann et al., 1990). This multi-faceted attack on DNA integrity and synthesis makes it a potent target for treating various solid tumors, including pancreatic and lung carcinomas (FDA Label, Gemzar).

Other names

DNADeoxyribonucleic acidDNA replication machineryDNA polymerase complexGenomic DNA

Gemcitabine metabolites (dFdCTP and dFdCDP) target DNA synthesis through two primary mechanisms: dFdCTP acts as a competitive substrate for DNA polymerase, leading to "masked chain termination" after the addition of one subsequent nucleotide, which prevents repair; dFdCDP inhibits ribonucleotide reductase (RNR), depleting the intracellular pool of deoxycytidine triphosphate (dCTP) and enhancing drug incorporation into DNA (StatPearls, 2023; Plunkett et al., 1995).